Online inquiry

IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ850MR)

This product GTTS-WQ850MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001024736.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ850MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6977MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ETI-204
GTTS-WQ15989MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ9909MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ2183MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ13208MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ14935MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ1966MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-15E
GTTS-WQ8358MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA hPAM4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW